Written questions by Andrew.

What steps his Department is taking to ensure that patients affected by changes to services at St Andrew’s Hospital in Northampton are transferred safely to appropriate alternative mental health provision.

The failings exposed at St Andrew’s Hospital in Northampton site are completely unacceptable. The accounts of poor care, patient harm, and sustained risks to vulnerable people are deeply distressing, and the safety and wellbeing of patients remains our foremost priority throughout this process.NHS England has required commissioners to begin identifying alternative inpatient placements for patients at St Andrew’s Hospital in Northampton following ongoing concerns about patient safety. Transfers are being managed carefully and in phases, based on individual clinical assessments, and patients will only move when a suitable alternative placement has been identified that can safely meet their needs. Enhanced clinical oversight has been put in place at the site, and NHS England is working closely with placing commissioners and provider networks to ensure transfers prioritise patient safety, continuity of care and compliance with the Mental Health Act where applicable.We recognise that many patients at St Andrew’s will have limited capacity to advocate for themselves. Their voices, and those of their families and representatives, must be central to this process. Enhanced advocacy provision is already in place, and patient communications including accessible and Easy Read formats are being developed to support understanding and reduce anxiety.After discussing with the NHS, a patient’s placing commissioner will talk with them to explain the options being considered for the best place for them to go next. They will listen to each patient’s preferences and feed these back to the NHS so they can be taken into account when making plans. Advanced advocacy support for patients is also in place. However, the final decision will also depend on the care needs of each patient and what services are available.Where a patient is receiving care in an adult secure service, decisions will also need to consider risk and any requirements from the Ministry of Justice that may apply. These factors help the team decide the most appropriate place for ongoing care.

What steps his Department is taking, with NHS England and integrated care boards, to address systemic failings in inpatient mental health care.

Anyone receiving mental health treatment should be able to expect consistently safe, high‑quality care. Families, staff, and the public deserve answers when things go wrong in mental health settings and it is vitally important that, where care falls short, we learn from any mistakes made to improve care across the National Health Service and to protect patients in the future. To this end, the Department has announced a statutory inquiry into the Tees, Esk and Wear Valleys NHS Foundation Trust.The Department and NHS England are committed to ensuring we put in place a modernised legislative framework through the Mental Health Act 2025 which upholds patient rights and voice and that provides stronger oversight, higher standards, and a system that better protects and supports some of the most vulnerable people in society, whilst keeping patients and the public safe. We are also prioritising eliminating inappropriate out of area placements. The Medium Term Planning Framework set a new national expectation to end all integrated care board-commissioned inappropriate out of area placements and the commissioning of locked rehabilitation services by March 2028.

What steps his Department is taking to ensure that inpatient mental health services have sufficient staffing levels and the appropriate skill mix to provide safe and therapeutic care.

As part of our mission to build a National Health Service that is fit for the future and that is there when people need it, the Government is recruiting an additional 8,500 mental health workers by the end of this Parliament. Over 8,000 of these workers have been recruited since July 2024, which will help to ease pressure on busy mental health services. We will publish a 10 Year Workforce Plan later this year to ensure the NHS has the right people in the right places to care for patients when they need it.

What assessment he has made of whether the modelling assumptions underpinning projected PSMA PET-CT activity volumes within the forthcoming PET-CT commissioning arrangements are (a) forward-looking and (b) reflect clinical demand.

NHS England is responsible for commissioning prostate‑specific membrane antigen (PSMA) radiotracers for positron emission tomography–computed tomography (PET‑CT) imaging for adults with high‑risk primary or recurrent prostate cancer. The commissioning policy, published in February 2025, sets out that PSMA PET‑CT should be available as a routinely commissioned imaging option within defined clinical criteria.NHS England undertook an assessment of current service provision, clinical evidence, and projected demand. This included reviewing existing PET‑CT activity across regions to identify variation and to ensure that projected activity volumes for prostate cancer aligned with current patterns of use and expected regional need. NHS England also considered evidence on current provision and expert advice when determining its recommended commissioning position.With respect to the modelling assumptions underpinning projected PSMA PET‑CT activity levels, NHS England’s assessment drew on a review of clinical evidence, expected diagnostic pathways, and forward‑looking estimates of the number of patients with high‑risk primary or recurrent prostate cancer who would meet the criteria for PSMA PET‑CT. The Clinical Panel and commissioning groups considered evidence on current provision, anticipated future utilisation, and the role of PSMA PET‑CT where conventional imaging leaves clinically important uncertainties. These assessments are reflected in the policy documentation and supporting evidence reviews published by NHS England.The commissioning policy documents including the Clinical Panel report, Evidence Review, and associated materials, are publicly available on the NHS England website at the following link:https://www.england.nhs.uk/publication/psma-radiotracers-in-petct-imaging-for-individuals-with-high-risk-primary-or-recurrent-prostate-cancer/

What assessment he has made of whether NHS England’s projected PET-CT activity volumes for prostate cancer under the forthcoming commissioning arrangements align with current regional activity levels; and what assessment he has made of any variance between projected and existing provision.

NHS England is responsible for commissioning prostate‑specific membrane antigen (PSMA) radiotracers for positron emission tomography–computed tomography (PET‑CT) imaging for adults with high‑risk primary or recurrent prostate cancer. The commissioning policy, published in February 2025, sets out that PSMA PET‑CT should be available as a routinely commissioned imaging option within defined clinical criteria.NHS England undertook an assessment of current service provision, clinical evidence, and projected demand. This included reviewing existing PET‑CT activity across regions to identify variation and to ensure that projected activity volumes for prostate cancer aligned with current patterns of use and expected regional need. NHS England also considered evidence on current provision and expert advice when determining its recommended commissioning position.With respect to the modelling assumptions underpinning projected PSMA PET‑CT activity levels, NHS England’s assessment drew on a review of clinical evidence, expected diagnostic pathways, and forward‑looking estimates of the number of patients with high‑risk primary or recurrent prostate cancer who would meet the criteria for PSMA PET‑CT. The Clinical Panel and commissioning groups considered evidence on current provision, anticipated future utilisation, and the role of PSMA PET‑CT where conventional imaging leaves clinically important uncertainties. These assessments are reflected in the policy documentation and supporting evidence reviews published by NHS England.The commissioning policy documents including the Clinical Panel report, Evidence Review, and associated materials, are publicly available on the NHS England website at the following link:https://www.england.nhs.uk/publication/psma-radiotracers-in-petct-imaging-for-individuals-with-high-risk-primary-or-recurrent-prostate-cancer/

Whether he plans to publish the methodology used by NHS England to calculate projected PET-CT activity volumes, including any assumptions relating to future demand growth and pathway developments in prostate cancer.

NHS England is responsible for commissioning prostate‑specific membrane antigen (PSMA) radiotracers for positron emission tomography–computed tomography (PET‑CT) imaging for adults with high‑risk primary or recurrent prostate cancer. The commissioning policy, published in February 2025, sets out that PSMA PET‑CT should be available as a routinely commissioned imaging option within defined clinical criteria.NHS England undertook an assessment of current service provision, clinical evidence, and projected demand. This included reviewing existing PET‑CT activity across regions to identify variation and to ensure that projected activity volumes for prostate cancer aligned with current patterns of use and expected regional need. NHS England also considered evidence on current provision and expert advice when determining its recommended commissioning position.With respect to the modelling assumptions underpinning projected PSMA PET‑CT activity levels, NHS England’s assessment drew on a review of clinical evidence, expected diagnostic pathways, and forward‑looking estimates of the number of patients with high‑risk primary or recurrent prostate cancer who would meet the criteria for PSMA PET‑CT. The Clinical Panel and commissioning groups considered evidence on current provision, anticipated future utilisation, and the role of PSMA PET‑CT where conventional imaging leaves clinically important uncertainties. These assessments are reflected in the policy documentation and supporting evidence reviews published by NHS England.The commissioning policy documents including the Clinical Panel report, Evidence Review, and associated materials, are publicly available on the NHS England website at the following link:https://www.england.nhs.uk/publication/psma-radiotracers-in-petct-imaging-for-individuals-with-high-risk-primary-or-recurrent-prostate-cancer/

What assessment he has made of the potential impact of the cost of shipping and air freight following the conflict in the Middle East on the supply of generic medicines to the UK; and what steps he is taking to mitigate that impact.

We continue to monitor the impact of the Middle East conflict on the medical supply chain, including on generic medicines. While we understand that transport costs have risen, there are currently no reported shortages of medicines due to the conflict.If shortages do occur, we have a range of well-established processes and tools to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals including pharmacists, so they can advise and support their patients.

What plans his Department has for non-specific symptom pathways for earlier diagnosis of leukaemia and other blood cancers.

Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes.To tackle the late diagnoses of blood cancers including leukaemia, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers, including leukaemia, are one of the most common cancer types diagnosed through these pathways.The NHS will improve early diagnosis and quicker treatment of blood cancers, including leukaemia, by expanding diagnostic services with investments in magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.

Whether the Life Sciences Sector Plan includes provision to protect and promote the resilience of the UK’s medicines supply chain.

A thriving life sciences sector is key to supporting the United Kingdom’s resilience and securing our medicines supply chain. Through the Life Sciences Sector Plan, the Government is making the UK one of the best places in the world to develop and manufacture new and innovative medicines and build onshore manufacturing capabilities.The sector plan commits to delivery of the Life Sciences Innovative Manufacturing Fund (LSIMF), which is providing up to £520 million in grants to companies to improve the UK’s manufacturing capability and resilience. So far, LSIMF grants have supported five companies, unlocking over £560 million of investment in life sciences manufacturing, and research and development, with further announcements expected in the coming weeks and months.

Whether his Department has made an assessment of regional variation in access to 24/7 interventional radiology services in England.

The Elective Reform Plan, which was published in January 2025, committed to increasing surgical and diagnostic capacity for services such as interventional radiology. This is a step towards returning to the National Health Service constitutional standard that 92% of patients wait no longer than 18 weeks from referral to consultant-led treatment.As a result of spending reviews in 2021 and 2025, diagnostic interventional radiology received capital funding for four interventional radiology suites.The Government has also committed £2.3 billion across diagnostics for the next three financial years. Trusts and regions are currently going through a competitive bidding process for this diagnostic funding, which is expected to conclude in spring 2026.

What steps his Department is taking to increase the availability of interventional radiology services in England.

The Elective Reform Plan, which was published in January 2025, committed to increasing surgical and diagnostic capacity for services such as interventional radiology. This is a step towards returning to the National Health Service constitutional standard that 92% of patients wait no longer than 18 weeks from referral to consultant-led treatment.As a result of spending reviews in 2021 and 2025, diagnostic interventional radiology received capital funding for four interventional radiology suites.The Government has also committed £2.3 billion across diagnostics for the next three financial years. Trusts and regions are currently going through a competitive bidding process for this diagnostic funding, which is expected to conclude in spring 2026.

What assessment his Department has made of current and projected workforce needs in interventional radiology; and what steps his Department is taking to support training and recruitment in this specialty.

We set out in the 10-Year Health Plan for England that over the next three years we will create 1,000 new specialty training posts, with a focus on specialties where there is the greatest need. We will set out next steps in due course.The Government is committed to training the staff we need, including doctors, to ensure patients are cared for by the right professional, when and where they need it. We will publish a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed services set out in the 10-Year Health Plan.

Pursuant to the Answer of 15 January 2026 to Question UIN 82954, what payments NHS England has made for waiting list data validation exercises (a) since 1 September 2025 and (b) in 2025–26 to date.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

What estimate his Department has made of the number of patient pathways removed from referral-to-treatment waiting lists following data validation exercises since 2020.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

How many patient pathways from the net reduction in the referral-to-treatment waiting list reported since 1 September 2025 were removed as a result of (a) completion of treatment and (b) data validation exercises.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

If he will bring forward legislative proposals to restrict the sale of high sugar and high caffeine energy drinks to children aged 16 and under before the next King's Speech.

The Government has a commitment to ban the sale of energy drinks to children under 16 years old, which is subject to a consultation. We subsequently ran a 12-week consultation, which was open from 3 September 2025 to 26 November 2025.We are carefully considering the responses to the consultation. We will set out further information on next steps in due course when we publish the Government’s response to the consultation.Should legislation be proposed following the consultation outcome the final timing for introducing legislation would depend on ministerial decisions following the consultation, impact assessment requirements, and the necessary parliamentary scrutiny.

What assessment he has made of the potential implications for his policies of responses to the consultation on the draft statutory guidance under the Down Syndrome Act 2022.

Through the implementation of the Down Syndrome Act 2022, the Government is striving to improve life outcomes for people with Down syndrome, raise awareness and understanding of their needs, and break down barriers to opportunity that they, and other disabled people, face.The Down Syndrome Act 2022 requires my Rt Hon. Friend, the Secretary of State for Health and Social Care, to give guidance to relevant authorities in health, social care, education, and housing services on the actions they should be taking to support the needs of people with Down syndrome. The public consultation on the draft guidance was launched on 5 November 2025 and will remain open until 30 March 2026. Once the consultation has closed, the Government will consider all consultation responses to inform the final guidance to be published.

If he will set out the timetable for the UK National Screening Committee’s review of screening for sudden cardiac death in young people; and whether the large-scale screening audit data due for publication in February 2026 will be considered as part of that review.

The UK National Screening Committee (UK NSC) is currently re-examining the evidence for sudden cardiac death screening in young people and will open a public consultation on this in the spring. The UK NSC secretariat is not aware of the audit referred to in this question. However, as the literature review needs to be completed and analysed before a consultation is published, any evidence published in February of this year will not be part of the UK NSC consultation.

What assessment his Department has made of the potential impact of electrocardiogram screening for young people engaged in organised sport, including the clinical effectiveness and cost effectiveness of such screening.

The Government is guided by the independent scientific advice of the UK National Screening Committee (UK NSC). It is only where the offer to screen provides more good than harm that a screening programme is recommended. The UK NSC makes its recommendations based on internationally recognised criteria and a rigorous evidence review and consultation process.Every sudden cardiac death of a young person is a tragedy. The UK National Screening Committee (UK NSC) is currently re-examining the evidence for sudden cardiac death screening in young people, including those involved in organised sports, and will open a public consultation on this in the spring.The Government welcome the UK NSC’s robust and rigorous approach to evaluating the benefits and harms of screening, as it is vital that screening policy is based on scientific evidence.

Whether the final statutory guidance issued under the Down Syndrome Act 2022 will include Down syndrome-specific training for health, education and social care professionals.

I refer the Rt Hon. Member to the answer I gave to the Hon. Member for Maidenhead on 5 January 2026 to Question 103131.